β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.
about
Antibiotic strategies in the era of multidrug resistanceCritical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infectionsNew Insight on Epidemiology and Management of Bacterial Bloodstream Infection in Patients with Hematological MalignanciesCarbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysisClinical management of infections caused by multidrug-resistant EnterobacteriaceaeBeyond Susceptible and Resistant, Part II: Treatment of Infections Due to Gram-Negative Organisms Producing Extended-Spectrum β-LactamasesEmpiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing EnterobacteriaceaeAnalysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data--The Influence of Different Parameters in a Routine Clinical Microbiology LaboratoryAn update on the management of urinary tract infections in the era of antimicrobial resistance.Emergence and dissemination of multi-resistant Gram negative Enterobacteriaceae: lessons to be learnt from local and national surveillance programs in Belgium.Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coliPediatric multicenter evaluation of the Verigene gram-negative blood culture test for rapid detection of inpatient bacteremia involving gram-negative organisms, extended-spectrum beta-lactamases, and carbapenemases.Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.Multidrug-resistant gram-negative bacteria colonization of healthy US military personnel in the US and AfghanistanMeropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.Oral amoxicillin-clavulanic Acid treatment in urinary tract infections caused by extended-spectrum Beta-lactamase-producing organisms.Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae.A statistical approach for determination of disk diffusion-based cutoff values for systematic characterization of wild-type and non-wild-type bacterial populations in antimicrobial susceptibility testing.Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremiaMechanisms of antimicrobial resistance in Gram-negative bacilli.Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-β-lactamase-producing Escherichia coli bacteremiaThe times they are a-changin': carbapenems for extended-spectrum-β-lactamase-producing bacteriaDecreased susceptibility to noncarbapenem antimicrobials in extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates in Toronto, CanadaImpact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.Klebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy.Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.Amikacin therapy for urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.Safe medication use based on knowledge of information about contraindications concerning cross allergy and comprehensive clinical interventionInoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria.A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing EnterobacteriaceaeIn vitro Effectiveness of Commercial Bacteriophage Cocktails on Diverse Extended-Spectrum Beta-Lactamase Producing Escherichia coli Strains.A multidisciplinary intervention to reduce infections of ESBL- and AmpC-producing, gram-negative bacteria at a University Hospital.Widespread dissemination of CTX-M-15 genotype extended-spectrum-β-lactamase-producing enterobacteriaceae among patients presenting to community hospitals in the southeastern United States.Detection of resistance to beta-lactamase inhibitors in strains with CTX-M beta-lactamases: a multicenter external proficiency study using a well-defined collection of Escherichia coli strains.Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infectionsThird-generation cephalosporin resistance of community-onset Escherichia coli and Klebsiella pneumoniae bacteremia in a secondary hospital.Clinical efficacy of β-lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrosManagement of Pneumonia and Blood Stream Infections with New Antibiotic Adjuvant Entity (Ceftriaxone + Sulbactam + Disodium Edetate)- A Novel Way to Spare Carbapenems.
P2860
Q26744091-FB14E19A-603E-4E7A-ABD9-2E249867AD4DQ26747429-12C97DB0-4675-4DF3-A3E2-6DA61CA41D95Q26799580-ED7D2EE4-BB20-420D-B49D-B60EBA713F2BQ27002495-B4CD5368-4FA7-420F-82D5-2FC1C25DC235Q28246841-9751FBB0-2457-417D-954A-A956B53EF2BEQ28249617-D3BE56A6-B923-4A89-9240-D6E92C157481Q28551534-D8A5BFA8-F41B-497E-ACA2-A3C1110C0A7CQ28552911-7DFBBA00-0DE2-472C-8116-ADDDEE222DC7Q30244815-7CEB1AD9-E01F-48D1-BB76-D099CE1520C4Q30368402-72FD5445-AECD-45E6-AB13-50DA151872E1Q33776486-0D08B284-E6BA-4E78-BB64-91D385A52DB6Q33900098-9DAFFF16-3AE3-4AB0-9CF6-4200DD36DAC7Q34057425-B0A8CD21-A719-40CC-AB5D-A3BC2F588CB6Q34577671-438C11BD-9697-42D9-BB9F-DEC7E589E008Q35030247-A77FD0D1-C482-4347-B30C-334E4DDB7F66Q35132012-3970DEC0-B61B-4CC1-B569-F043B0139B36Q35278325-AA374E6D-73F0-46F7-8929-6B562754F41AQ35552650-AC208ADE-E182-42EA-9658-169B384FA05BQ35607484-A7435037-3BC0-4A38-8A8A-6583F8D1A18AQ35715650-9AB94BEA-B05E-446B-BB35-2240B39AA403Q35935319-253EC2D1-B23F-4837-B42D-F39D49925491Q35960721-1B21D869-AE10-4E92-90FC-CD400A2DBC90Q35960751-70706E83-E5A0-453E-BB55-31943E074A4EQ36086414-66C59F20-4E1D-49B3-9412-9D1CCCC352EFQ36086501-2F97474A-E65E-44E7-AC69-31CD7D1304A0Q36150730-22A5EA07-97A2-47B6-88BF-CC1089F716C2Q36438937-E203135A-C974-4EA2-9C20-738E5F23F7A5Q36461121-DEE011B2-E548-4490-A76B-9465AFC6F1B0Q36648388-BCCCEAB8-8451-4F6F-B97C-9B75DCB4E0D8Q36785886-DA76DC98-BC48-4B5E-82EC-BEFDDA20DA8BQ36969726-B0E856BA-F80A-40E9-BB2D-36BA76047845Q37023191-1E9978AE-4AD3-4CC1-B0BA-EBA39BE23A12Q37389468-DE7C04EA-B388-4CC8-AB62-5A0EE92D8BE5Q37510069-31254177-F1DB-425F-BAFB-03ECC67FD893Q37544721-0203D20A-B755-4AA4-9B63-1D29154434D4Q37546694-CBE25F7B-4B92-4209-99C7-AA191C191CE0Q37559129-C51C8368-412A-43B0-A883-29B155335C7BQ37598820-BD0358CB-CB3A-47A7-B34B-12823D29C19AQ37612207-D5738D46-721A-448C-9A69-AEFCA2AA8CC2Q37630039-8679DD07-94C6-4080-B5C2-EBD868C29A2E
P2860
β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
β-Lactam/β-lactam inhibitor co ...... alysis of prospective cohorts.
@en
β-Lactam/β-lactam inhibitor co ...... alysis of prospective cohorts.
@nl
type
label
β-Lactam/β-lactam inhibitor co ...... alysis of prospective cohorts.
@en
β-Lactam/β-lactam inhibitor co ...... alysis of prospective cohorts.
@nl
prefLabel
β-Lactam/β-lactam inhibitor co ...... alysis of prospective cohorts.
@en
β-Lactam/β-lactam inhibitor co ...... alysis of prospective cohorts.
@nl
P2093
P2860
P356
P1476
β-Lactam/β-lactam inhibitor co ...... alysis of prospective cohorts.
@en
P2093
Encarnación Picón
Extended-Spectrum Beta-Lactama ...... e Infección Hospitalaria Group
María Dolores Navarro
Pilar Retamar
Álvaro Pascual
P2860
P304
P356
10.1093/CID/CIR790
P407
P577
2011-11-04T00:00:00Z